Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loratadine + mometasone furoate
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intranasal, Oral
01
Overview
Loratadine + mometasone furoate is a combination therapy used for the treatment of allergic rhinitis. This combination pairs loratadine, a non-sedating antihistamine, with mometasone furoate, an intranasal corticosteroid. Loratadine works by blocking histamine receptors, while mometasone furoate reduces inflammation in the nasal passages. Clinical studies have shown that this combination provides similar benefits to mometasone furoate monotherapy for treating seasonal allergic rhinitis symptoms.
02
Targets
GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on loratadine + mometasone furoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on loratadine + mometasone furoate.